Previous 10 | Next 10 |
Generated net FUROSCIX® revenue of $3.8 million Ended Q3 2023 with cash, cash equivalents and short-term investments o f $90.2 million Company to host investor conference call and webcast today, Wednesday, November 8, at 4:30pm ET BURLINGTON, Mass., Nov. 08, 2023 ...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
scPharmaceuticals Inc. (SCPH) is expected to report $-0.36 for Q3 2023
BURLINGTON, Mass., Nov. 01, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that scPharmace...
2023-09-27 00:40:20 ET Summary Positive FDA feedback for Furoscix's label expansion into chronic kidney disease signals the potential for significant market growth. Introduction of a higher concentration auto-injector formulation of Furoscix could reduce costs and enhance patient ...
2023-09-19 13:22:31 ET More on scPharmaceuticals Seeking Alpha’s Quant Rating on scPharmaceuticals Historical earnings data for scPharmaceuticals Sizing Up scPharmaceuticals scPharmaceuticals Inc. (SCPH) Q2 2023 Earnings Call Transcript scPharm...
Company advancing plans to expand the FUROSCIX franchise to include an 80mg/1ml auto-injector as an additional delivery system designed to provide greater flexibility to heart failure patients Agency confirms no additional clinical data required to pursue label expansion of FUROSCIX int...
2023-09-13 14:13:58 ET Summary Today, we take our first look at scPharmaceuticals Inc., which has received positive analyst commentary but has a large short position in the stock. The company just launched its franchise product FUROSCIX in February of this year and management beli...
BURLINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today ...
2023-08-10 22:38:02 ET scPharmaceuticals Inc. (SCPH) Q2 2023 Earnings Conference Call August 10, 2023 16:30 ET Company Participants PJ Kelleher - Investor Relations John Tucker - Chief Executive Officer Steve Parsons - Senior Vice President, Commercial Rachae...
News, Short Squeeze, Breakout and More Instantly...
scPharmaceuticals Inc. Company Name:
SCPH Stock Symbol:
NASDAQ Market:
scPharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States SiNtx Technologies Inc. (SINT) rose 208.7% to $0.1698 on volume of 325,435,783 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 76.7% to $0.5039 on volume of 314,353,673 shares Greenwave Technology Solutions Inc. (GWAV) ros...
Generated 1Q 2024 net FUROSCIX ® revenue of $6.1 million, despite an estimated 10% impact to doses filled resulting from the Change Healthcare cyberattack Ended 1Q 2024 with cash and cash equivalents o f $58.4 million Company to host investor conference call and web...
BURLINGTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and com...